Search Within

Mark E Robson

Formats
  1. Journal Article (382)
  2. Meeting Abstract (259)
  3. Review (10)
  4. Book Section (7)
  5. Guidelines (7)
  6. Editorial (6)
  7. Miscellaneous (4)
  8. Correspondence (1)
  9. Research Letter (1)
Groups
  1. Breast Medicine Service (677)
  2. Department of Medicine (677)
  3. Population Sciences Research Program (677)
  4. Solid Tumor Oncology Division (677)
  5. Survivorship Research (677)
  6. GSK Faculty (376)

More Groups

People
  1. Kenneth Offit (280)
  2. Zsofia Stadler (116)
  3. Larry Norton (89)
  4. Vijai Joseph (79)
  5. Diana Mandelker (74)
  6. Michael Berger (67)

More People

Years
  1. 2025 (3)
  2. 2024 (32)
  3. 2023 (41)
  4. 2022 (34)
  5. 2021 (46)
  6. 2020 (65)

More Years

Publications
  1. Journal of Clinical Oncology (163)
  2. Cancer Research (50)
  3. Breast Cancer Research and Treatment (33)
  4. JNCI: Journal of the National Cancer Institute (20)
  5. Annals of Oncology (19)
  6. Clinical Cancer Research (17)

More Publications

Publishers
  1. American Society of Clinical Oncology (185)
  2. American Association for Cancer Research (82)
  3. Springer (66)
  4. Nature Publishing Group (60)
  5. Elsevier Inc. (50)
  6. Oxford University Press (43)

More Publishers

Results (677)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer
    Journal Article

    Mai, N.; dos Anjos, C. H.; Razavi, P.; Safonov, A.; Patil, S.; Chen, Y.; Drago, J. Z.; Modi, S.; Bromberg, J. F.; Dang, C. T.; more...
    npj Breast Cancer (2024)

    Fulltext@MSK | Save
  • Population-based germline breast cancer gene association studies and meta-analysis to inform wider mainstream testing
    Journal Article

    Rowlands, C. F.; Allen, S.; BalmanĖƒa, J.; Domchek, S. M.; Evans, D. G.; Hanson, H.; Hoogerbrugge, N.; James, P. A.; Nathanson, K. L.; Robson, M.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2
    Meeting Abstract

    Tung, N. M.; Robson, M. E.; Nanda, R.; Li, T.; Vinayak, S.; Shah, P. D.; Khoury, K.; Kimmick, G. G.; Santa-Maria, C. A.; Brufsky, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HOPE: Harnessing olaparib, palbociclib, and endocrine therapy for BRCA1/2-associated HR+, HER2- metastatic breast cancer
    Meeting Abstract

    Shah, P. D.; Torres, A.; Aaron, M.; Narayan, V.; Knollman, H. M.; Bradbury, A. R.; DeMichele, A.; Robson, M. E.; Tung, N. M.; Domchek, S. M.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2-early breast cancer (EBC) treated with endocrine therapy (ET) in the US
    Meeting Abstract

    Razavi, P.; Ahmed, M.; Roush, A.; Parikh, R.; Hitchens, A.; Shen, S.; Safonov, A.; Jhaveri, K. L.; Robson, M. E.; Peacock, N. W.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Personalized circulating tumor DNA for minimal residual disease and dynamic assessment in patients undergoing neoadjuvant chemotherapy for breast cancer: Preliminary analysis from MSK-LINC
    Meeting Abstract

    Kim, H. K.; An, J. A. R.; Smith, C. G.; Kim, J.; Cabel, L.; Moiso, E.; Ferraro, E.; Safonov, A.; Nelson, K.; Szuhany, K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Immunotherapy related patient-reported outcomes from five randomized controlled trials in patients with triple negative breast cancer: A systematic review
    Meeting Abstract

    Sha, C.; Liu, M.; Goldberg, J.; Norton, L.; Robson, M. E.; Zhi, I.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Overall survival analysis of first line CDK4/6 inhibitors in a large real-world cohort of patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer
    Meeting Abstract

    Ferraro, E.; Moiso, E.; Safonov, A.; Cabel, L.; Loudon, L.; Dang, C. T.; Shen, S.; Jhaveri, K. L.; Robson, M. E.; Chandarlapaty, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Predicting CDK4/6 inhibitors outcomes in pts with HR+/HER2-metastatic breast cancer: A machine learning approach
    Meeting Abstract

    Moiso, E.; Ferraro, E.; Cabel, L.; Safonov, A.; Ahmed, M.; An, J. A. R.; Jhaveri, K. L.; Norton, L.; Robson, M. E.; Modi, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • FLT1 activation in cancer cells promotes PARP-inhibitor resistance in breast cancer
    Journal Article

    Tai, Y.; Chow, A.; Han, S.; Coker, C.; Ma, W.; Gu, Y.; Estrada Navarro, V.; Kandpal, M.; Hibshoosh, H.; Kalinsky, K.; more...
    EMBO Molecular Medicine (2024)

    Fulltext@MSK | Save